Comparison of two methods for the analysis of CSF Aβ and tau in the diagnosis of Alzheimer’s disease

American Journal of Neurodegenerative Disease

Simon YL Ching¹  Peter K Panegyres¹  John Beilby¹  Matthew Faull¹  Anna I Jarmolowicz¹ 

关键词: Alzheimer’s disease;    cerebrospinal fluid;    amyloid beta;    tau;    P-tau;    T-tau;    biomarkers;    clinical diagnosis;   

DOI  :  

学科分类：精神健康和精神病学

来源: e-Century Publishing Corporation

【 摘 要 】

Introduction: Biomarkers represent a promising adjunct to clinical techniques in the diagnosis of Alzheimer’s Disease (AD) and other neurodegenerative diseases. At present, the potential of cerebrospinal fluid (CSF) biomarkers in diagnosing AD has been suggested but the degree of clinical utility is yet to be defined due to variability between studies. In this paper we compare the performance of two cerebrospinal fluid assay methods in predicting clinically diagnosed AD. Methods: CSF biomarker concentrations for Aβ_1-42, P-tau_181P and T-tau were analysed using INNOTEST (ELISA) and INNO-BIA AlzBio3 (Luminex) assay methods from Innogenetics, Belgium. Patients were clinically diagnosed based on NINCDS-ADRDA criteria supplemented with structural MRI, ¹⁸F-fluorodeoxy-glucose positron emission tomography (FDG-PET) and cognitive profiling. Results: An abnormally low Aβ_1-42 was the most useful biomarker in predicting clinical AD. Depending on the assay method, the predictive accuracy remained constant or improved slightly when abnormalities in P-tau_181P and T-tau were considered in addition to Aβ_1-42. The Luminex method with our optimised reference concentrations performed best for patients ≤ 65 years with sensitivity = 1 and a specificity = 0.60 for both Aβ_1-42 and when one or more abnormal biomarkers were considered. Conclusion: Given accurate, robust and reproducible CSF analytical methods, of which the Luminex method seems the most useful and practicable, our investigation suggests that measuring CSF Aβ_1-42, P-tau and T-tau has utility in the diagnosis of probable AD and, when used with clinical diagnostic techniques, seems especially helpful in the diagnosis of AD with onset prior to the age of 65 years.

【 授权许可】

Unknown